IGF-1 LR3 Research for Muscle Wasting
An evidence-based overview of research examining IGF-1 LR3 in the context of muscle wasting. This page synthesizes findings from peer-reviewed literature.
Research Summary
IGF-1 signaling inhibits FOXO transcription factors that drive muscle atrophy. In animal models of muscle wasting (including muscular dystrophy), IGF-1 LR3 improved muscle function. Clinical trials for wasting conditions have used native IGF-1, not the LR3 variant.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. IGF-1 LR3 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.